Immunic (IMUX) Research & Development (2013 - 2026)
Immunic (IMUX) posted Research & Development of $25.6 million for Q1 2026, up 34.39% sequentially from $19.1 million in Q4 2025, and up 19.01% YoY from $21.5 million in Q1 2025.
Immunic (IMUX) Research & Development (2013 - 2026) Analysis & Trends
Immunic has reported Research & Development for 14 years, with the latest figure at $25.6 million in Q1 2026.
- Quarterly Research & Development rose 19.01% year-over-year to $25.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.1 million (up 3.9% YoY) and the FY2025 annual result came in at $82.0 million, up 2.42% from the prior year.
- Research & Development climbed to $25.6 million in Q1 2026 per IMUX's latest filing, from $19.1 million in the prior quarter.
- Over five years, Research & Development peaked at $25.6 million in Q1 2026 and troughed at $16.5 million in Q3 2022.
- A 5-year average of $20.1 million and a median of $20.0 million in 2025 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2024: Research & Development surged 51.45% in 2022, then decreased 18.41% in 2024.
- Over 5 years, Research & Development stood at $20.7 million in 2022, then retreated by 7.0% to $19.3 million in 2023, then gained by 12.1% to $21.6 million in 2024, then retreated by 11.79% to $19.1 million in 2025, then soared by 34.39% to $25.6 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $25.6 million, $19.1 million, and $20.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Immunic | 682.77 Mn | 682.77 Mn | - | 25.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.93 Mn |
| Mar 31, 2026 | 25.63 Mn |
| Dec 31, 2025 | 19.07 Mn |
| Sep 30, 2025 | 20.01 Mn |
| Jun 30, 2025 | 21.37 Mn |
| Mar 31, 2025 | 21.53 Mn |
| Dec 31, 2024 | 21.62 Mn |
| Sep 30, 2024 | 21.37 Mn |
| Jun 30, 2024 | 18.32 Mn |
| Mar 31, 2024 | 18.74 Mn |
| Dec 31, 2023 | 19.28 Mn |
| Sep 30, 2023 | 19.80 Mn |
| Jun 30, 2023 | 21.17 Mn |
| Mar 31, 2023 | 22.96 Mn |
| Dec 31, 2022 | 20.74 Mn |
| Sep 30, 2022 | 16.54 Mn |
| Jun 30, 2022 | 16.54 Mn |
| Mar 31, 2022 | 17.45 Mn |
| Dec 31, 2021 | 18.38 Mn |
| Sep 30, 2021 | 15.48 Mn |